InsidersTradesSigma
Total declarations
Companies
▲ Purchases (8 ops.)
▼ Sales (0 ops.)
Insider track record
OtherDisclosed buys
8
Disclosed sells
0
T+90 hit rate
14%
T+90 mean return
-18.1%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by BERMAN ROBERT ANDREW. Director active across 2 companies, notably Hancock Jaffe Laboratories, Inc.. Aggregated, 10 disclosures have been logged. Breakdown: 8 buys · 0 sell. Total volume traded: €119k. Activity tracked since 18 May 2021. The latest transaction was filed on 19 December 2024 (Acquisition). Regulator: SEC (Form 4). All data is free.
Declarations10 total
12,000 shares@ US$2.5532.0% of flowCommon StockSEC:0001493152-24-050865:0
Ideal exit: 15 Sept 2025 (T+270)
2,500 shares@ US$3.800.14% mcap14.3% of flowCommon StockSEC:0001493152-22-017957:0
Ideal exit: 24 Mar 2023 (T+270)
200,000 sharesCommon StockSEC:0001493152-21-030335:0
200,000 sharesCommon StockSEC:0001493152-21-030335
2,000 shares@ US$7.4314.1% of flowCommon StockSEC:0001493152-21-029430
Ideal exit: 16 Aug 2022 (T+270)
2,000 shares@ US$7.430.20% mcap20.8% of flowCommon StockSEC:0001493152-21-029430:0
Ideal exit: 16 Aug 2022 (T+270)
2,000 shares@ US$7.870.21% mcap22.0% of flowCommon StockSEC:0001493152-21-029229:0
Ideal exit: 13 Aug 2022 (T+270)
2,000 shares@ US$7.8715.0% of flowCommon StockSEC:0001493152-21-029229
Ideal exit: 13 Aug 2022 (T+270)
▲
3,000 shares@ US$5.4750.0% of flowCommon Stock, $0.00001 par valueSEC:0001493152-21-012298
Ideal exit: 12 Feb 2022 (T+270)
▲
3,000 shares@ US$5.4750.0% of flowCommon Stock, $0.00001 par valueSEC:0001493152-21-012298:0
Ideal exit: 12 Feb 2022 (T+270)
10 of 10 declarations
About BERMAN ROBERT ANDREW
Robert Andrew Berman is a director at Hancock Jaffe Laboratories, Inc. and enVVeno Medical Corp.
